

Biology of CD305 and its Implication in Maternal-Fetal Immune Tolerance

Qiang Fu* and Jiangnan Xue

Department of Immunology, Binzhou Medical University, China

*Corresponding Author: Qiang Fu, Department of Immunology, Binzhou Medical University, Yantai, 264003, China.

Received: September 12, 2015; Published: September 24, 2015

Abstract

Immune responses are controlled by the opposing actions of activating and inhibitory signals. Inhibitory receptors are expressed to prevent excessive immune responses. Paternal alloantigen coming from trophoblasts could stimulate maternal lymphocytes during pregnancy. The mechanisms of maternal-fetal immune tolerance in the successful pregnancy are remained to be elucidated. CD305 belongs to the inhibitory receptors family, which are involved in controlling the balance of the immune system to prevent improper activation. Upon interaction with their ligands, CD305 could attenuate the signals provided by activating receptors, thereby increasing the threshold for activation. In this review, we summarize new research progress about CD305 in the differential regulation and immune inhibitory functions in many kinds of leukocytes and discuss its significance and implication in maternal-fetal immune tolerance.

Keywords: CD305; CD306; LAIR; Maternal-fetal immune tolerance

Introduction

Leukocyte receptor complex (LRC) comprises a large cluster of cell surface receptors including the killer immunoglobulin-like receptors (KIR) and the leukocyte Ig-like receptors (LILRs), osteoclast-associated receptor (OSCAR) and glycoprotein VI (GPVI). These receptors share ancient homology in the structure and function. CD305, as a new member in the LRC, has been reported as 9.1C3 [1,2], P40 [3] and leukocyte-associated Ig-like receptor-1 (LAIR-1) [4] in the past two decades. CD305 was named in the 8th international HLDA conference in 2004 [5], and its 84% homologous molecule which has been reported as LAIR-2, also got the number CD306. As an immunoglobulin super family (IgSF) type I TM protein receptor of 287 amino acids, CD305 contains a single extracellular C2-type Ig-like domain with two ITIMs (VTYAQLx24 ITYAAV) in its cytoplasmic tail. Due to its functional and structural characteristics both in gene and protein, CD305 has been paid more attention recently in the research of differential regulation and immune inhibitory functions.

The location and Ligands of CD305

The encoded gene of CD305, just like other two important immunoglobulin super family receptors: KIRs and LILRs, is also located in the LRC in human chromosome 19q13.4. Gene blast analysis shows that an inverse duplication event has taken place as a late evolutionary event, centered about the CD305 genes in the LRC [6]. Therefore CD305 is genetically and functionally related to many of the immunoreceptors present in the LRC. CD305 is expressed on CD34⁺ hemopoietic progenitors [2,7] and almost all immune cells, including NK cells, B and T lymphocytes, thymocytes, monocytes [3,4,8], DCs [9], eosinophils [7], basophils and mast cells [10].

CD305 binds both transmembrane and extracellular matrix collagens [11,12]. As the functional ligands, collagens can inhibit the activation of primary immune cells and cell lines in vitro [11,13]. Although some transmembrane receptors, such as integrins, discoidin domain receptors (DDR) and Glycoprotein VI (GPVI) have been confirmed to recognize the typical collagen triple helix and have the potential to signal [14], both human and mouse CD305 bind collagen specifically whereas other cell surface proteins gave no binding, except for the related inhibitory leukocyte immunoglobulin-like receptor subfamily B member 4 (Lilrb4, CD85K, Gp49B) [15].

Immune cells present in the bloodstream do not encounter matrix collagens under physiologic conditions. But their exposure to the collagen-rich sub endothelium will result in abrogation or inhibition of immune cell function through the inhibitory signal transduced by CD305 into the cell [11]. Its high affinity for collagen also implicates a possible role for CD305 as an adhesion molecule for immune cells. CD305 could inhibit GPVI activation in cell lines that both express these receptors [16]. The inhibitory and activating collagen receptors CD305 and GPVI are simultaneously expressed on a subset of mega karyoblasts and promega karyocytes, which might reveal a role for CD305 in the regulation of collagen-activation through GPVI and in the differentiation of mega karyoblasts [17].

The interaction of CD305 with collagen has been explored by a combination of X-ray crystallography, NMR titrations and mutagenesis. The crystal structure of the collagen-binding domain of CD305 closely resembles the KIR2DL2, LILRA5 and GPVI D1 domains. The available crystal structures will facilitate the development of compounds targeted at specifically modulating immune responses via the CD305/collagens interaction or thrombosis through GPVI [18]. Moreover, the existence of mRNA coding for CD305 isoform lacking the transmembrane domain [4], suggests that soluble CD305 (sCD305) can block the interaction of the transmembrane receptor with collagens. This will contribute to the exploration of specific means for intervention in collagen-induced signaling in immunological disorder diseases.

The function and signaling pathway of CD305

The differential and immunological activities of leukocytes are controlled by numerous interactions between membrane receptors and their ligands. The differential regulation and immune inhibitory functions of CD305 have been extensively described in many kinds of leukocytes.

The differentiation and proliferation of hemopoietic progenitors could be influenced by collagens in the bone marrow [2,19]. CD305 could inhibit the differentiation of monocyte-derived DCs in the presence of GM-CSF in vitro [9] and GM-CSF-dependent proliferation and protein kinase B activation in primary leukemia cells [20]. Sustained engagement of CD305 also induced apoptosis in leukemia cell lines [21]. The expression of CD305 is also related to neutrophil differentiation. CD305 is expressed on the immature neutrophils, but very low on the surface of peripheral blood neutrophils [7]. Our recent study shows that CD305 is expressed on the early stage of human primary megakaryocytes and the cross-linking of CD305 could negatively regulate cytokine-mediated differentiation of megakaryocytes derived from cord blood CD34⁺ cells [22].

CD305 could inhibit the cytotoxic activity of NK cells using specific monoclonal antibodies [3,4,8] and abrogate the cytotoxic activity of T cells induced by CD3 cross-linking or antigen stimulation [4,8,23,24]. CD305 signaling leads to down regulation of calcium mobilization in primary human B cells induced by B cell receptor cross-linking and in U937 cells mediated by FcR-induced degranulation of RBL-2H3 [25-27]. What's more, similar to CD85j (LIR-1, ILT2) and CD152 (CTLA-4), the cross-linking of CD305 could result in the down-regulation of IL-10, IL-8, TNF- α release and the inhibition of IgG and IgE production [28]. Therefore, CD305 could act at the end of the immune response, when the factors causing it have disappeared. However, tumor cells, which have been known to up regulate ECM and TM collagens, could down regulate immune responses through CD305 [29]. These researches suggest that extracellular matrix (ECM) collagens can regulate the activities of immune cells in vivo, and set thresholds of activation on immune cells that have migrated into or are resident in tissues. Therefore, it is meaningful to illuminate the immune regulation role of CD305/collagens in the collagen-rich tissues or collagen-producing cells.

Upon receptor aggregation, CD305 operating like a classical ITIM-encoding receptor, ITIMs are phosphorylated by Src kinases, which recruit SHP-1 and SHP-2 but not SHIP. Both ITIMs are required for optimal phosphatase recruitment and full inhibitory function, although mutants with only one functional ITIM are still capable to inhibit cellular responses of the NK-like YT.2C2 cells and basophilic cells [26,30]. Co immunoprecipitation studies demonstrated that the exclusive phosphotyrosine-containing protein associated with SHP-1 in Jurkat T cells under physiological conditions is CD305, suggesting that it is an important negative regulating pathway in T cells and other immune cells [30,31]. In DT40 cells deficient in SHP-1 and SHP-2, CD305 appears to recruit Csk, which negatively regulates Src kinase activity [32-34]. This interaction required the SH2 domain of Csk and phosphorylation of the N-terminal ITIM of CD305 [32]. Csk has also been shown to be recruited to another inhibitory LRC member, LILRB2, and the non-LRC encoded receptor, signal-regulatory

Citation: Qiang Fu and Jiangnan Xue. "Biology of CD305 and its Implication in Maternal-Fetal Immune Tolerance". *EC Microbiology* 2.2 (2015): 288-293.

protein (SIRP) [35,36]. These data suggest there are some common signaling pathways among different inhibitory receptors in conditions where PTPs are limiting. Interestingly, Programmed cell death (PCD) elicited via CD305 was not blocked by different caspase inhibitors, at variance with apoptosis induced via CD95/Fas, which was prevented by the caspase-1 and caspase-8 specific inhibitors. As blocking of NF-KB activation has been shown to rescue sensitivity to anti-cancer drugs in solid tumors, CD305 may represent a possible target for pharmacological approaches aimed to potentiate anti-leukemic therapy [21].

In summary, CD305, as an ITIM-bearing receptor, plays an important role not only in the differentiation of hemopoietic progenitors, monocyte-derived DCs, neutrophils and megakaryocytes, but also in the activation control of NK, T and B cells in various phases of the immune response. The extensive function of CD305 and its unique signaling pathway need to be illuminated through more researches.

The application and implication of CD305

CD305 belongs to the immune inhibitory receptors family, which are involved in controlling the balance of the immune system to prevent improper activation or overactivation, which may result in tissue damage or autoimmune diseases. Upon interaction with their ligands, these receptors attenuate the signals provided by activating receptors, thereby increasing the threshold for activation. Therefore, CD305 has great significance in immune tolerance.

Resting and activated NK cells derived from the chronic active Epstein-Barr virus (CAEBV) patient showed a marked and significant loss of CD305 expression. It would be worthwhile for clinicians with cases of CAEBV to assess NK cells for defects in CD305 expression [37]. CD306, a soluble receptor, also binds collagens and could act as a negative regulator of CD305 signaling by masking available collagen-binding sites for CD305 [19]. Proteolytically shed sCD305 could conceivably perform a similar function to CD306. sCD305 can be detected in the supernatant of stimulated lymphocytes and in the sera of transplantation and HFRS patients [38]; CD306 is present in the synovial fluid of patients suffering from rheumatoid arthritis (RA) [19,38]. Both sCD305 and CD306 could be detected in the plasma and urine of healthy control subjects and patients with RA. Urinary levels of both proteins were significantly increased in RA patients, and CD306 levels in urine were significantly correlated with markers of inflammation [39]. Recent research in SLE patients with low CD305 expression on B cells has shown that CD305/collagen engagement delivered a lower inhibiting signal on Ig production, which indicates defective CD305 expression and function in SLE B lymphocytes, possible contributing to an altered control of B lymphocytes behavior [40]. Although the exact function of sCD305 and CD306 in those patients remains to be investigated, they could be used as a predictor of immune response and related diseases. The clinical implication about the changes of sCD305 and CD306 in urine or serum samples is worthy to be paid more attention.

A global gene expression microarray analysis of surplus chorionic villus sampling (CVS) tissues identified CD306 as down-regulated in the first trimester of pregnancies destined for preeclampsia [41]. In situ hybridization (ISH) and immunohistochemistry (IHC) staining for CD306 detected specific, highly localized expression at the leading edge of EVT anchoring cell columns in first trimester placentas [42]. The precise restriction of this protein only to the sites of EVT invasion strongly suggests that it functions to regulate this invasion through the binding to the extracellular material into which these trophoblasts invade. The decreased CD306 expression noted in first trimester placentas that ultimately developed preeclampsia further suggests that alterations in CD306 may play an etiologic role in preeclampsia [42]. An inspiring finding was that the CD305 mRNA was high in trophoblast cells, being in the top 25 of all transcripts in both VT and EVT. But there is no surface expression at the protein level on trophoblast cells [43]. Because we have shown that CD305 serves as a negative regulator of megakaryocytopoiesis [22], the hypothesis is that the abnormal translation and expression of CD305 on the invading trophoblasts could result in the inactivation and inhibition of trophoblasts' proliferation and invasion through the binding of collagen in some diseases potentially associated with abnormal EVT invasion, and CD306 could prevent these processes. Activated CD4⁺T cells were the main producers of CD306 in RA patients [39]; could the decidua immune cells (DIC) be another source of CD306 or the main source of sCD305?

CD305 is a special inhibitory receptor due to its extensive expression on almost all cells of the immune system and its collagen ligands, which are also extensively expressed in many kinds of tissues. CD306 is a more potent antagonist of CD305 function in vivo [39]. The absence of CD306 in lower primates, and the restriction of this gene to the great apes, suggests that the emergence of CD306 may

have occurred shortly before or nearly parallel with this rapid co-evolution of lineage III KIR receptors with MHC-C. Although CD305-deficient mice shows certain phenotypic characteristics distinct from wild type mice, including increased numbers of splenic B, regulatory T, and dendritic cells, they are healthy and fertile, which suggest that any adverse effects of CD305 absence may be balanced in vivo by other inhibitory receptors in mice [44]. Therefore, the rapid evolution within the leukocyte receptor sub cluster containing CD306 and the KIR genes suggests that these molecules and their effects on placentation may have played an important role in the evolution of higher primates [42]. The interplay of CD305 with sCD305 and CD306 need to be elucidated: What is the role of this interplay in the placentation? What is the exact regulating mechanism of CD305 on the differentiation and function of DIC and what is the feed-back control of CD305 mediated effects on cell proliferation and differentiation in deciduas? Further identification of CD305 and CD306 abnormalities in the maternal-fetal interface may help determine their functions in EVT invasion and immunoregulation and the primary etiology of RSA, preeclampsia, fetal growth restriction or preterm birth, and may provide diagnostic biomarkers and/or therapeutic targets for treating these diseases.

KIRs are associated with preeclampsia [45], and LILRB1 are associated with HLA-G for normal placentation [46]. Therefore, the illustration of the interplay of CD305 and CD306 and their cooperation with other immune receptors, especially those encoded in the LRC, just like KIRs and LILRs would be helpful for mapping the whole clear pictures about the maternal-fetal immune tolerance.

The literature reviewed here represents major researches in the understanding of CD305 and CD306. With the recent identification and characterization of CD305 and CD306 in differentiation and immune regulation, the next exploring researches about their roles in maternal-fetal immune tolerance and placentation are possible and clearly.

Bibliography

1. Burns GF, *et al.* "Human natural killer cells, activated lymphocyte killer cells, and monocytes possess similar cytotoxic mechanisms". *Proceedings of the National Academy of Sciences of the United States of America* 80.24 (1983): 7606-7610.
2. Ouyang W, *et al.* "9.1C3 is identical to LAIR-1, which is expressed on hematopoietic progenitors". *Biochemical and Biophysical Research Communications* 310.4 (2003): 1236-1240.
3. Poggi A, *et al.* "p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans". *European Journal of Immunology* 25.2 (1995): 369-376.
4. Meyaard L, *et al.* "LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes". *Immunity* 7.2 (1997): 283-290.
5. Warren HS. "The Eighth Human Leucocyte Differentiation Antigen (HLDA8) Workshop: natural killer cell section report". *Cell Immunology* 236.1 (2005): 17-20.
6. Wende H, *et al.* "Extensive gene duplications and a large inversion characterize the human leukocyte receptor cluster". *Immunogenetics* 51 (2000): 703-713.
7. Verbrugge A, *et al.* "Differential expression of leukocyte-associated Ig-like receptor-1 during neutrophil differentiation and activation". *Journal of Leukocyte Biology* 79.4 (2006): 828-836.
8. Poggi A, *et al.* "p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes". *International Immunology* 9.9 (1997): 1271-1279.
9. Poggi A, *et al.* "p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-macrophage colony-stimulating factor". *European Journal of Immunology* 28.7 (1998): 2086-2091.
10. Florian S, *et al.* "Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies". *Allergy* 61.9 (2006): 1054-1062.
11. Lebbink RJ, *et al.* "Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1". *The Journal of Experimental Medicine* 203.6 (2006): 1419-1425.
12. Lebbink RJ, *et al.* "Identification of multiple potent binding sites for human leukocyte associated Ig-like receptor LAIR on collagens II and III". *Matrix Biology* 28.4 (2009): 202-210.

13. Lebbink RJ, *et al.* "Mouse leukocyte-associated Ig-like receptor-1 (mLAIR-1) functions as an inhibitory collagen-binding receptor on immune cells". *International Immunology* 19.8 (2007): 1011-1019.
14. Leitinger B and Hohenester E. "Mammalian collagen receptors". *Matrix Biology* 26.3 (2007): 146-155.
15. Jiang L and Barclay AN. "New assay to detect low-affinity interactions and characterization of leukocyte receptors for collagen including leukocyte-associated Ig-like receptor-1 (LAIR-1). *European Journal of Immunology* 39.4 (2009): 1167-1175.
16. Tomlinson MG, *et al.* "Collagen promotes sustained glycoprotein VI signaling in platelets and cell lines". *Journal of Thrombosis and Haemostasis* 5.11 (2007): 2274-2283.
17. Steevels TA, *et al.* "Co-expression of the collagen receptors leukocyte-associated immunoglobulin-like receptor-1 and glycoprotein VI on a subset of megakaryoblasts". *Haematologica* 95.12 (2010): 2005-2012.
18. Brondijk TH, *et al.* "Crystal structure and collagen-binding site of immune inhibitory receptor LAIR-1: unexpected implications for collagen binding by platelet receptor GPVI". *Blood* 115.7 (2010): 1364-14373.
19. Meyaard L. "The inhibitory collagen receptor LAIR-1 (CD305)". *Journal of Leukocyte Biology* 83.4 (2008): 799-803.
20. Zocchi MR, *et al.* "Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells". *European Journal of Immunology* 31.12 (2001): 3667-3675.
21. Poggi A, *et al.* "Engagement of the leukocyte-associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias". *European Journal of Immunology* 30.10 (2000): 2751-8.
22. Xue J, *et al.* "Leukocyte-associated immunoglobulin-like receptor-1 is expressed on human megakaryocytes and negatively regulates the maturation of primary megakaryocytic progenitors and cell line". *Biochemical and Biophysical Research Communications* 405.1 (2011): 128-133.
23. Maasho K, *et al.* "The inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) is expressed at high levels by human naive T cells and inhibits TCR mediated activation". *Molecular Immunology* 42.12 (2005): 1521-1530.
24. Meyaard L, *et al.* "Leukocyte-associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells". *Journal of Immunology* 162.10 (1999): 5800-5804.
25. Fournier N, *et al.* "FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells". *Journal of Immunology* 165.3 (2000): 1197-1209.
26. Verbrugge A, *et al.* "Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment". *Journal of Immunology* 15.11 (2003): 1349-1358.
27. van der Vuurst de Vries AR, *et al.* "Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling". *European Journal of Immunology* 29.10 (1999): 3160-3167.
28. Merlo A, *et al.* "Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes". *Clinical Diagnostics Lab Immunology* 12.6 (2005): 705-712.
29. Rygiel TP, *et al.* "Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1". *Molecular Immunology* 49.1-2 (2011): 402-406.
30. Xu M, *et al.* "Identification and characterization of leukocyte-associated Ig-like receptor-1 as a major anchor protein of tyrosine phosphatase SHP-1 in hematopoietic cells". *Journal of Biological Chemistry* 275.23 (2000): 17440-17446.
31. Sathish JG, *et al.* "Constitutive association of SHP-1 with leukocyte-associated Ig-like receptor-1 in human T cells". *Journal of Immunology* 166.3 (2001): 1763-1770.
32. Verbrugge A, *et al.* "Leukocyte-associated Ig-like receptor-1 has SH2 domain-containing phosphatase-independent function and recruits C-terminal Src kinase". *European Journal of Immunology* 36.1 (2006): 190-198.
33. Imamoto A and Soriano P. "Disruption of the csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice". *Cell* 73.6 (1993): 1117-1124.
34. Nada S, *et al.* "Constitutive activation of Src family kinases in mouse embryos that lack Csk". *Cell* 73.6 (1993): 1125-1135.

35. Sayos J., *et al.* "Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j". *Biochemical Biophysical Research Communication* 324.2 (2004): 640-647.
36. Veillette A., *et al.* "High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages". *Journal of Biological Chemistry* 273.35 (1998): 22719-22728.
37. Aoukaty A., *et al.* "Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells". *Journal of Clinical Immunology* 23.2 (2003): 141-145.
38. Ouyang W., *et al.* "Establishment of an ELISA system for determining soluble LAIR-1 levels in sera of patients with HFRS and kidney transplant". *Journal of Immunological Methods* 292.1-2(2004): 109-117.
39. Nordkamp MJ., *et al.* "Enhanced secretion of leukocyte-associated immunoglobulin-like receptor 2 (LAIR-2) and soluble LAIR-1 in rheumatoid arthritis: LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than is soluble LAIR-1". *Arthritis & Rheumatology* 63.12 (2011): 3749-3757.
40. Colombo BM., *et al.* "Defective Expression and Function of the Leukocyte Associated Ig-like Receptor 1 in B Lymphocytes from Systemic Lupus Erythematosus Patients". *PLoS ONE* 7.2 (2012): e31903.
41. Founds SA., *et al.* "Altered global gene expression in first trimester placentas of women destined to develop preeclampsia". *Placenta* 30.1 (2009): 15-24.
42. Founds SA., *et al.* "LAIR2 localizes specifically to sites of extravillous trophoblast invasion". *Placenta* 31.10 (2010): 880-885.
43. Apps R., *et al.* "Genome-wide expression profile of first trimester villous and extravillous human trophoblast cells". *Placenta* 32.1 (2011): 33-43.
44. Xiaobin Tang., *et al.* "Leukocyte-Associated Ig-like Receptor-1-Deficient Mice Have an Altered Immune Cell Phenotype". *The Journal of Immunology* 188.2 (2012): 548-558.
45. Hiby SE., *et al.* "Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success". *The Journal of Experimental Medicine* 200.8 (2004): 957-965.
46. Apps R., *et al.* "A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1". *European Journal of Immunology* 37.7 (2007): 1924-1937.

Volume 2 Issue 2 September 2015

© All rights are reserved by Qiang Fu and Jiangnan Xue.